|
|
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.UZ |
First Approval Date31 Dec 2021 |
A Real-world Study:Disease Outcome and Safety of JT001 in Patients With Coronavirus Disease 2019 (COVID-19)
Real-world disease outcomes and safety in patients with mild to moderate COVID-19 treated with JT001
Effect of Clarithromycin or Cyclosporine on Pharmacokinetics of Deuterium Hydrobromide Ramidvir Tablets in Healthy Chinese Subjects
This study is a single-center, open label, self-controlled phase I clinical study, to evaluate the effects of clarithromycin or cyclosporine on pharmacokinetics of deuterium hydrobromide ramidvir tablets in healthy Chinese subjects.
An Open-label, Single-dose, Phase I Study to Assess the Pharmacokinetics and Safety of JT001 in Subjects With Mild and Moderate Hepatic Impairment Compared to Subjects With Normal Hepatic Function
Evaluate the pharmacokinetic differences of the main metabolite 116-N1 of JT001 in subjects with mild and moderate liver function impairment and those with normal liver function, providing a basis for formulating clinical medication plans for patients with liver function impairment;
100 Clinical Results associated with Shanghai Vinnerna Biosciences Co., Ltd.
0 Patents (Medical) associated with Shanghai Vinnerna Biosciences Co., Ltd.
100 Deals associated with Shanghai Vinnerna Biosciences Co., Ltd.
100 Translational Medicine associated with Shanghai Vinnerna Biosciences Co., Ltd.